Endoxifen - Atossa Therapeutics
Alternative Names: (Z)-endoxifenLatest Information Update: 15 Apr 2025
At a glance
- Originator Atossa Genetics
- Developer Atossa Therapeutics; Weill Cornell Medicine
- Class Antineoplastics; Methylamines; Phenyl ethers; Small molecules; Stilbenes
- Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast cancer; Ductal carcinoma; HER2 negative breast cancer
- Preclinical Triple negative breast cancer
- No development reported Gynaecomastia; Ovarian cancer
Most Recent Events
- 25 Mar 2025 Efficacy and adverse events data from phase II trial for Breast Cancer released by Atossa Therapeutics
- 31 May 2024 Efficacy data form phase II I-SPY trial in Breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 28 May 2024 No recent reports of development identified for clinical-Phase-Unknown development in Ovarian-cancer(Recurrent) in USA (PO)